{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T05:01:33Z","timestamp":1780203693359,"version":"3.54.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178143","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:41:21Z","timestamp":1757572881000},"page":"178143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["YN1548: A novel small-molecule agonist of human glucagon-like peptide-1 receptor for the treatment of type 2 diabetes mellitus and obesity"],"prefix":"10.1016","volume":"1006","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3530-340X","authenticated-orcid":false,"given":"In-Gyu","family":"Je","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Kwang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong Jun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Mi","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Tae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0407-3018","authenticated-orcid":false,"given":"Ki-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejphar.2025.178143_bib1","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20165646","article-title":"Non-clinical studies in the process of new drug development - part II: good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies","volume":"49","author":"Andrade","year":"2016","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"9","key":"10.1016\/j.ejphar.2025.178143_bib2","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"Pioneer 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178143_bib3","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.ejphar.2025.178143_bib4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1208\/s12248-009-9111-6","article-title":"Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine","volume":"11","author":"Bolger","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.ejphar.2025.178143_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/DDDT.S348055","article-title":"The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in diabetes-related neurodegenerative diseases","volume":"16","author":"Cheng","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"issue":"13","key":"10.1016\/j.ejphar.2025.178143_bib6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1001\/archinte.161.13.1581","article-title":"Impact of overweight on the risk of developing common chronic diseases during a 10-year period","volume":"161","author":"Field","year":"2001","journal-title":"Arch. Intern. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.ejphar.2025.178143_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American association of clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr. Pract."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178143_bib8","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","article-title":"A small-molecule oral agonist of the human glucagon-like peptide-1 receptor","volume":"65","author":"Griffith","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178143_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41467-017-02661-3","article-title":"Lack of beta-arrestin signaling in the absence of active G proteins","volume":"9","author":"Grundmann","year":"2018","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178143_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4093\/dmj.2018.0055","article-title":"The evidence for an obesity paradox in type 2 diabetes mellitus","volume":"42","author":"Han","year":"2018","journal-title":"Diabetes Metab. J."},{"issue":"9","key":"10.1016\/j.ejphar.2025.178143_bib11","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1517\/17425255.2014.934671","article-title":"The application of allometric scaling principles to predict pharmacokinetic parameters across species","volume":"10","author":"Huang","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178143_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2337\/cd19-0079","article-title":"Oral semaglutide","volume":"38","author":"Hughes","year":"2020","journal-title":"Clin. Diabetes"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178143_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bph.15497","article-title":"The therapeutic potential of GLP-1 receptor biased agonism","volume":"179","author":"Jones","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178143_bib15","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"8","key":"10.1016\/j.ejphar.2025.178143_bib16","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s40262-024-01408-w","article-title":"Physiologically based pharmacokinetic model of OATP1B substrates with a nonlinear mixed effect approach: estimating empirical in vitro-to-in vivo scaling factors","volume":"63","author":"Li","year":"2024","journal-title":"Clin. Pharmacokinet."},{"issue":"549","key":"10.1016\/j.ejphar.2025.178143_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat7650","article-title":"Manifold roles of beta-arrestins in GPCR signaling elucidated with siRNA and CRISPR\/Cas9","volume":"11","author":"Luttrell","year":"2018","journal-title":"Sci. Signal."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178143_bib18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.178143_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol. Metabol."},{"issue":"10400","key":"10.1016\/j.ejphar.2025.178143_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(23)01201-1","article-title":"Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists","volume":"402","author":"Nauck","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178143_bib21","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1210\/endo-119-4-1467","article-title":"Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas","volume":"119","author":"Orskov","year":"1986","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178143_bib22","first-page":"5219","article-title":"Glucagon-like peptide-1 potentiates glucose-stimulated insulin secretion via the transient receptor potential melastatin 2 channel","volume":"14","author":"Pang","year":"2017","journal-title":"Exp. Ther. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178143_bib23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/M23-2788","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians","volume":"177","author":"Qaseem","year":"2024","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178143_bib24","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s40618-015-0385-5","article-title":"Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study","volume":"38","author":"Rigato","year":"2015","journal-title":"J. Endocrinol. Investig."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178143_bib25","first-page":"1079","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat. Med. (N. Y., NY, U. S.)"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178143_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.ejphar.2025.178143_bib27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/phar.1507","article-title":"GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents","volume":"34","author":"Trujillo","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejphar.2025.178143_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9676754","article-title":"A role of glucose overload in diabetic cardiomyopathy in nonhuman primates","volume":"2021","author":"Wang","year":"2021","journal-title":"J. Diabetes Res."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178143_bib29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178143_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/cells13010065","article-title":"GLP1 receptor agonists-effects beyond obesity and diabetes","volume":"13","author":"Wilbon","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178143_bib31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R binding and activation by peptide and non-peptide agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2025.178143_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:40:39Z","timestamp":1780202439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925008970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"alternative-id":["S0014299925008970"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178143","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"YN1548: A novel small-molecule agonist of human glucagon-like peptide-1 receptor for the treatment of type 2 diabetes mellitus and obesity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178143"}}